Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Ceftazidime-avibactam was used to treat 77 patients with carbapenem-resistant Enterobacteriaceae (CRE) infections at our center. Thirty- and 90-day survival rates were 81% and 69%, respectively; these rates were higher than those predicted by SAPS II and SOFA scores at the onset of infection. Clinic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Shields, Ryan K., Nguyen, M. Hong, Chen, Liang, Press, Ellen G., Kreiswirth, Barry N., Clancy, Cornelius J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2018
Témata:
Clinical Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5923134/
https://ncbi.nlm.nih.gov/pubmed/29507064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02497-17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky